EX-99.1 2 a20233006_991exhibit.htm EX-99.1 Document

Exhibit 99.1
draftof8k050418image1.gif
            
AMEDISYS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

BATON ROUGE, Louisiana (July 26, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2023.
Three-Month Periods Ended June 30, 2023 and 2022

◦Net service revenue decreased $4.9 million to $553.0 million compared to $557.9 million in 2022.
◦Net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of $125.5 million in costs associated with our merger transactions, compared to net income attributable to Amedisys, Inc. of $29.6 million in 2022.
◦Net loss attributable to Amedisys, Inc. per diluted share of $2.46 compared to net income attributable to Amedisys, Inc. per diluted share of $0.91 in 2022.

Adjusted Quarterly Results*

•Adjusted EBITDA of $74.6 million compared to $74.4 million in 2022.
•Adjusted net service revenue of $553.0 million compared to $566.3 million in 2022.
•Adjusted net income attributable to Amedisys, Inc. of $44.9 million compared to $48.0 million in 2022.
•Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.37 compared to $1.47 in 2022.

Six-Month Periods Ended June 30, 2023 and 2022

◦Net service revenue increased $6.3 million to $1,109.4 million compared to $1,103.1 million in 2022.
◦Net loss attributable to Amedisys, Inc. of $55.0 million, which is inclusive of $126.2 million in costs associated with our merger transactions, compared to net income attributable to Amedisys, Inc. of $61.3 million in 2022.
◦Net loss attributable to Amedisys, Inc. per diluted share of $1.69 compared to net income attributable to Amedisys, Inc. of $1.87 in 2022.

Adjusted Year to Date Results*

•Adjusted EBITDA of $132.5 million compared to $140.7 million in 2022.
•Adjusted net service revenue of $1,109.4 million compared to $1,111.5 million in 2022.
•Adjusted net income attributable to Amedisys, Inc. of $77.6 million compared to $88.1 million in 2022.
•Adjusted net income attributable to Amedisys, Inc. per diluted share of $2.38 compared to $2.69 in 2022.



* See pages 2 and 14 - 16 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.
The supplemental slides provided in connection with the second quarter 2023 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the second quarter results and has decided to suspend guidance on 2023 financial performance.
1

Non-GAAP Financial Measures
This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net (loss) income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted net income attributable to Amedisys, Inc., defined as net (loss) income attributable to Amedisys, Inc. excluding certain items; and (4) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net (loss) income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.
Additional Information
Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes, home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 18,500 employees in 522 care centers within 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 455,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.
We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.
2

Forward-Looking Statements
When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of Amedisys or to satisfy any other condition in a timely manner or at all; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19") on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
Contact:    Investor Contact:                Media Contact:            
Amedisys, Inc.                    Amedisys, Inc.
        Nick Muscato                    Kendra Kimmons
        Chief Strategy Officer             Vice President, Marketing & Communications
    (615) 928- 5452                    (225) 299-3720
        IR@amedisys.com             kendra.kimmons@amedisys.com
    

3

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)
 For the Three-Month 
Periods Ended June 30,		For the Six-Month
Periods Ended June 30,
 2023202220232022
Net service revenue$552,968 $557,890 $1,109,357 $1,103,147 
Operating expenses:
Cost of service, inclusive of depreciation297,455 316,211 612,465 621,031 
General and administrative expenses:
Salaries and benefits125,504 127,758 251,843 251,238 
Non-cash compensation9,108 5,148 12,381 12,495 
Depreciation and amortization4,725 6,220 9,168 14,228 
Other78,381 54,912 143,326 108,552 
Total operating expenses515,173 510,249 1,029,183 1,007,544 
Operating income37,795 47,641 80,174 95,603 
Other income (expense):
Interest income742 36 1,148 49 
Interest expense(7,502)(8,311)(15,019)(11,484)
Equity in earnings (loss) from equity method investments7,991 659 8,114 (744)
Merger termination fee(106,000)— (106,000)— 
Miscellaneous, net4,743 331 4,061 664 
Total other expense, net(100,026)(7,285)(107,696)(11,515)
(Loss) income before income taxes(62,231)40,356 (27,522)84,088 
Income tax expense(18,250)(11,319)(28,050)(23,338)
Net (loss) income(80,481)29,037 (55,572)60,750 
Net loss attributable to noncontrolling interests206 542 543 500 
Net (loss) income attributable to Amedisys, Inc.$(80,275)$29,579 $(55,029)$61,250 
Basic earnings per common share:
Net (loss) income attributable to Amedisys, Inc. common stockholders$(2.46)$0.91 $(1.69)$1.88 
Weighted average shares outstanding32,579 32,522 32,568 32,538 
Diluted earnings per common share:
Net (loss) income attributable to Amedisys, Inc. common stockholders$(2.46)$0.91 $(1.69)$1.87 
Weighted average shares outstanding32,579 32,681 32,568 32,722 

4

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
June 30, 2023
(unaudited)		December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents$95,377 $40,540 
Restricted cash15,784 13,593 
Patient accounts receivable278,785 296,785 
Prepaid expenses13,774 11,628 
Other current assets22,824 26,415 
Total current assets426,544 388,961 
Property and equipment, net of accumulated depreciation of $90,523 and $101,36436,399 16,026 
Operating lease right of use assets85,142 102,856 
Goodwill1,244,679 1,287,399 
Intangible assets, net of accumulated amortization of $17,714 and $14,604104,744 101,167 
Other assets84,894 79,836 
Total assets$1,982,402 $1,976,245 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$38,557 $43,735 
Payroll and employee benefits123,234 125,387 
Accrued expenses137,359 137,390 
Termination fee paid by UnitedHealth Group106,000 — 
Current portion of long-term obligations31,465 15,496 
Current portion of operating lease liabilities25,786 33,521 
Total current liabilities462,401 355,529 
Long-term obligations, less current portion369,896 419,420 
Operating lease liabilities, less current portion59,634 69,504 
Deferred income tax liabilities28,085 20,411 
Other long-term obligations1,629 4,808 
Total liabilities921,645 869,672 
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding— — 
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,030,397 and 37,891,186 shares issued; 32,608,325 and 32,511,465 shares outstanding38 38 
Additional paid-in capital
768,789 755,063 
Treasury stock, at cost, 5,422,072 and 5,379,721 shares of common stock(464,688)(461,200)
Retained earnings702,643 757,672 
Total Amedisys, Inc. stockholders’ equity1,006,782 1,051,573 
Noncontrolling interests53,975 55,000 
Total equity1,060,757 1,106,573 
Total liabilities and equity$1,982,402 $1,976,245 


5

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
(Amounts in thousands, except statistical information)
(Unaudited)
 For the Three-Month
Periods Ended June 30,		For the Six-Month
Periods Ended June 30,
 2023202220232022
Cash Flows from Operating Activities:
Net (loss) income$(80,481)$29,037 $(55,572)$60,750 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)6,199 6,220 11,893 14,228 
Non-cash compensation9,108 5,148 12,381 12,495 
Amortization and impairment of operating lease right of use assets8,349 12,367 16,971 22,463 
Loss on disposal of property and equipment426 526 356 531 
Loss on personal care divestiture— — 2,186 — 
Merger termination fee106,000 — 106,000 — 
Deferred income taxes5,332 2,798 8,104 6,003 
Equity in (earnings) loss from equity method investments(7,991)(659)(8,114)744 
Amortization of deferred debt issuance costs247 247 495 495 
Return on equity method investments966 718 2,753 2,428 
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable15,338 (2,726)7,862 (21,344)
Other current assets5,817 (12,350)1,689 (4,468)
Operating lease right of use assets(1,019)(913)(1,937)(1,662)
Other assets355 (27)244 220 
Accounts payable(1,274)6,613 (4,731)4,498 
Accrued expenses4,034 22,046 4,775 29,529 
Other long-term obligations(3,151)(166)(3,179)(223)
Operating lease liabilities(7,496)(11,470)(15,456)(20,657)
Net cash provided by operating activities60,759 57,409 86,720 106,030 
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets6 6 25 28 
Proceeds from the sale of property and equipment100 — 100 37 
Purchases of property and equipment(1,394)(1,880)(2,744)(2,782)
Investments in technology assets(6,457)(323)(6,667)(559)
Purchase of cost method investment— — — (15,000)
Proceeds from personal care divestiture— — 47,787 — 
Acquisitions of businesses, net of cash acquired— (73,311)(350)(73,311)
Net cash (used in) provided by investing activities(7,745)(75,508)38,151 (91,587)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options75 686 75 772 
Proceeds from issuance of stock under employee stock purchase plan938 906 1,754 1,891 
Shares withheld to pay taxes on non-cash compensation(2,180)(80)(3,488)(4,762)
Noncontrolling interest contributions376 300 376 952 
Noncontrolling interest distributions(427)(303)(712)(975)
Proceeds from borrowings under revolving line of credit15,000 298,500 23,000 298,500 
Repayments of borrowings under revolving line of credit (15,000)(283,500)(23,000)(283,500)
Principal payments of long-term obligations(5,680)(3,204)(60,993)(6,975)
Purchase of company stock— (17,351)— (17,351)
Payment of accrued contingent consideration(4,055)— (4,055)— 
Purchase of noncontrolling interest— — (800)— 
Net cash used in financing activities(10,953)(4,046)(67,843)(11,448)
Net increase (decrease) in cash, cash equivalents and restricted cash42,061 (22,145)57,028 2,995 
Cash, cash equivalents and restricted cash at beginning of period69,100 70,909 54,133 45,769 
Cash, cash equivalents and restricted cash at end of period$111,161 $48,764 $111,161 $48,764 
6

For the Three-Month 
Periods Ended June 30,		For the Six-Month 
Periods Ended June 30,
2023202220232022
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest$6,377 $2,625 $13,031 $4,489 
Cash paid for income taxes, net of refunds received$15,468 $22,426 $15,820 $22,977 
Cash paid for operating lease liabilities$8,516 $12,383 $17,394 $22,319 
Cash paid for finance lease liabilities$2,864 $378 $5,321 $735 
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities$7,719 $15,387 $14,802 $26,590 
Right of use assets obtained in exchange for finance lease liabilities$7,154 $1,100 $27,944 $1,316 
Reductions to right of use assets resulting from reductions to operating lease liabilities$14,994 $2,464 $15,135 $2,763 
Reductions to right of use assets resulting from reductions to finance lease liabilities$525 $— $894 $— 
Accrued contingent consideration$— $19,195 $— $19,195 
Noncontrolling interest contribution$— $— $— $8,900 
Days revenue outstanding (1)43.4 46.8 43.4 46.8 

(1) Our calculation of days revenue outstanding at June 30, 2023 and 2022 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended June 30, 2023 and 2022, respectively.
7

AMEDISYS, INC. AND SUBSIDIARIES
SEGMENT INFORMATION
(Amounts in millions, except statistical information)
(Unaudited)
Segment Information - Home Health
 For the Three-Month Periods
Ended June 30,
 20232022
Financial Information (in millions) (6):
Medicare$219.8 $222.0 
Non-Medicare130.0 119.9 
Net service revenue349.8 341.9 
Cost of service, inclusive of depreciation194.5 194.7 
Gross margin155.3 147.2 
General and administrative expenses90.2 88.8 
Depreciation and amortization1.2 1.5 
Operating income$63.9 $56.9 
Same Store Growth(1):
Medicare revenue(1 %)(9 %)
Non-Medicare revenue10 %(3 %)
Total admissions4 %— %
Total volume(2)
3 %(2 %)
Key Statistical Data - Total(3)(6):
Admissions97,453 94,063 
Recertifications45,808 45,821 
Total volume143,261 139,884 
Medicare completed episodes74,848 78,321 
Average Medicare revenue per completed episode(4)
$3,005 $3,051 
Medicare visits per completed episode(5)
12.5 13.2 
Visiting clinician cost per visit$99.81 $97.68 
Clinical manager cost per visit11.14 10.77 
Total cost per visit$110.95 $108.45 
Visits1,752,449 1,795,611 
8

 For the Six-Month Periods
Ended June 30,
 20232022
Financial Information (in millions) (6):
Medicare$435.2 $446.1 
Non-Medicare257.9 231.5 
Net service revenue693.1 677.6 
Cost of service, inclusive of depreciation391.5 379.9 
Gross margin301.6 297.7 
General and administrative expenses179.3 172.0 
Depreciation and amortization2.3 2.4 
Operating income$120.0 $123.3 
Same Store Growth(1):
Medicare revenue(4 %)(4 %)
Non-Medicare revenue11 %— %
Total admissions6 %1 %
Total volume(2)
4 %(1 %)
Key Statistical Data - Total(3)(6):
Admissions199,416 185,827 
Recertifications89,133 88,677 
Total volume288,549 274,504 
Medicare completed episodes148,411 152,764 
Average Medicare revenue per completed episode(4)
$2,990 $3,032 
Medicare visits per completed episode(5)
12.4 13.1 
Visiting clinician cost per visit$99.83 $97.41 
Clinical manager cost per visit11.13 10.77 
Total cost per visit$110.96 $108.18 
Visits3,527,655 3,511,822 
(1)Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2)Total volume includes all admissions and recertifications.
(3)Total includes acquisitions, start-ups and denovos.
(4)Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration at 2% and 1% for the three-month periods ended March 31, 2022 and June 30, 2022, respectively, and the reinstatement of sequestration at 2% for the three and six-month period ended June 30, 2023.
(5)Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
(6)Prior year has been recast to conform to the current year presentation.

9

Segment Information - Hospice
 For the Three-Month Periods
Ended June 30,
 20232022
Financial Information (in millions):
Medicare$188.2 $187.5 
Non-Medicare11.0 10.9 
Net service revenue199.2 198.4 
Cost of service, inclusive of depreciation98.8 107.4 
Gross margin100.4 91.0 
General and administrative expenses47.9 51.6 
Depreciation and amortization0.7 0.6 
Operating income$51.8 $38.8 
Same Store Growth(1):
Medicare revenue— %— %
Hospice admissions(6 %)6 %
Average daily census(2 %)— %
Key Statistical Data - Total(2):
Hospice admissions12,395 13,359 
Average daily census12,918 13,249 
Revenue per day, net$169.47 $164.55 
Cost of service per day$84.03 $89.05 
Average discharge length of stay90 87 
 For the Six-Month Periods
Ended June 30,
 20232022
Financial Information (in millions):
Medicare$370.9 $370.0 
Non-Medicare21.7 21.4 
Net service revenue392.6 391.4 
Cost of service, inclusive of depreciation200.2 213.8 
Gross margin192.4 177.6 
General and administrative expenses95.8 102.9 
Depreciation and amortization1.3 1.3 
Operating income$95.3 $73.4 
Same Store Growth(1):
Medicare revenue— %— %
Hospice admissions(6 %)4 %
Average daily census(1 %)(1 %)
Key Statistical Data - Total(2):
Hospice admissions25,393 27,245 
Average daily census12,825 13,086 
Revenue per day, net$169.15 $165.28 
Cost of service per day$86.24 $90.24 
Average discharge length of stay90 88 
(1)Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2)Total includes acquisitions and denovos.
10

Segment Information - Personal Care (1)
 For the Three-Month Periods
Ended June 30,
 20232022
Financial Information (in millions):
Medicare$— $— 
Non-Medicare— 14.9 
Net service revenue— 14.9 
Cost of service, inclusive of depreciation— 11.4 
Gross margin— 3.5 
General and administrative expenses— 2.3 
Depreciation and amortization— — 
Operating income$— $1.2 
Key Statistical Data - Total:
Billable hours— 472,523 
Clients served— 7,759 
Shifts— 201,996 
Revenue per hour$— $31.59 
Revenue per shift$— $73.89 
Hours per shift— 2.3
 For the Six-Month Periods
Ended June 30,
 20232022
Financial Information (in millions):
Medicare$— $— 
Non-Medicare15.0 28.9 
Net service revenue15.0 28.9 
Cost of service, inclusive of depreciation11.1 22.2 
Gross margin3.9 6.7 
General and administrative expenses2.3 4.5 
Depreciation and amortization— 0.1 
Operating income$1.6 $2.1 
Key Statistical Data - Total:
Billable hours440,464 923,555 
Clients served7,892 8,591 
Shifts191,379 395,738 
Revenue per hour$33.97 $31.27 
Revenue per shift$78.19 $72.99 
Hours per shift2.3 2.3
(1) We completed the sale of our personal care business on March 31, 2023.











11

Segment Information - High Acuity Care

 For the Three-Month Periods
Ended June 30,
 20232022
Financial Information (in millions) (1):
Medicare$— $— 
Non-Medicare4.0 2.7 
Net service revenue4.0 2.7 
Cost of service, inclusive of depreciation4.2 2.7 
Gross margin(0.2)— 
General and administrative expenses5.3 5.2 
Depreciation and amortization0.8 0.8 
Operating loss$(6.3)$(6.0)
Key Statistical Data - Total:
Full risk admissions186 104 
Limited risk admissions348 241 
Total admissions534 345 
Full risk revenue per episode$9,303 $11,278 
Limited risk revenue per episode$6,098 $5,316 
Number of admitting joint venture markets11 9 
 For the Six-Month Periods
Ended June 30,
 20232022
Financial Information (in millions) (1):
Medicare$— $— 
Non-Medicare8.7 5.2 
Net service revenue8.7 5.2 
Cost of service, inclusive of depreciation9.7 5.1 
Gross margin(1.0)0.1 
General and administrative expenses9.7 9.5 
Depreciation and amortization1.6 1.6 
Operating loss$(12.3)$(11.0)
Key Statistical Data - Total:
Full risk admissions344 210 
Limited risk admissions807 468 
Total admissions1,151 678 
Full risk revenue per episode$10,236 $10,672 
Limited risk revenue per episode$5,878 $5,541 
Number of admitting joint venture markets11 9 
(1)Prior year has been recast to conform to the current year presentation.








12



Segment Information - Corporate
 
 For the Three-Month Periods
Ended June 30,
 20232022
Financial Information (in millions) (1):
General and administrative expenses$69.6 $40.0 
Depreciation and amortization2.0 3.3 
Total operating expenses$71.6 $43.3 
 For the Six-Month Periods
Ended June 30,
 20232022
Financial Information (in millions) (1):
General and administrative expenses$120.4 $83.4 
Depreciation and amortization4.0 8.8 
Total operating expenses$124.4 $92.2 
(1)Prior year has been recast to conform to the current year presentation.



13

AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands)
(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:
For the Three-Month Periods
Ended June 30, 		For the Six-Month Periods
Ended June 30,
2023202220232022
Net (loss) income attributable to Amedisys, Inc.$(80,275)$29,579 $(55,029)$61,250 
Add:
        Income tax expense18,250 11,319 28,050 23,338 
        Interest expense, net6,760 8,275 13,871 11,435 
        Depreciation and amortization6,199 6,220 11,893 14,228 
        Certain items(1)
123,704 23,609 133,691 35,059 
        Interest component of certain items(1)
— (4,652)— (4,652)
Adjusted EBITDA(2)(6)
$74,638 $74,350 $132,476 $140,658 

Adjusted Net Service Revenue Reconciliation:
For the Three-Month Periods
Ended June 30,		For the Six-Month Periods
Ended June 30,
2023202220232022
Net service revenue$552,968 $557,890 $1,109,357 $1,103,147 
Add:
        Certain items(1)
— 8,374 — 8,374 
Adjusted net service revenue(3) (6)
$552,968 $566,264 $1,109,357 $1,111,521 


Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:
For the Three-Month Periods
Ended June 30,		For the Six-Month Periods
Ended June 30,
2023202220232022
Net (loss) income attributable to Amedisys, Inc.$(80,275)$29,579 $(55,029)$61,250 
Add:
        Certain items(1)
125,153 18,373 132,642 26,847 
Adjusted net income attributable to Amedisys, Inc.(4)(6)
$44,878 $47,952 $77,613 $88,097 

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:
For the Three-Month Periods
Ended June 30,		For the Six-Month Periods
Ended June 30,
2023202220232022
Net (loss) income attributable to Amedisys, Inc. common stockholders per diluted share$(2.46)$0.91 $(1.69)$1.87 
Add:
        Certain items(1)
3.83 0.56 4.06 0.82 
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(5)(6)
$1.37 $1.47 $2.38 $2.69 

14

(1)    The following details the certain items for the three and six-month periods ended June 30, 2023 and 2022:

Certain Items (in thousands):
For the Three-Month Periods
Ended June 30, 2023		For the Six-Month Periods
Ended June 30, 2023
(Income) Expense(Income) Expense
Certain Items Impacting Cost of Service, Inclusive of Depreciation:
Clinical optimization and reorganization costs$— $114 
Certain Items Impacting General and Administrative Expenses:
Acquisition and integration costs1,101 2,768 
Executive Board of Directors/CEO transition award3,435 4,185 
Merger-related legal and professional fees19,451 20,171 
Clinical optimization and reorganization costs567 3,737 
Personal care divestiture11 525 
Certain Items Impacting Total Other Income (Expense):
Other (income) expense, net (includes $106,000 merger termination fee)99,139 102,191 
Total$123,704 $133,691 
Net of tax$125,153 $132,642 
Diluted EPS$3.83 $4.06 
For the Three-Month Periods
Ended June 30, 2022		For the Six-Month Periods
Ended June 30, 2022
(Income) Expense(Income) Expense
Certain Items Impacting Net Service Revenue:
Contingency accrual$8,374 $8,374 
Certain Items Impacting Cost of Service:
COVID-19 costs1,803 5,536 
Clinical optimization and reorganization costs195 195 
Fuel supplement1,016 1,353 
Integration costs1,401 1,401 
Certain Items Impacting General and Administrative Expenses:
Acquisition and integration costs5,323 6,701 
COVID-19 costs84 237 
Executive Board of Directors/CEO transition award— 3,500 
Legal fees - non-routine190 241 
Clinical optimization and reorganization costs869 869 
Legal settlement(1,058)(1,058)
Certain Items Impacting Total Other Income (Expense):
Interest component of certain items4,652 4,652 
Other (income) expense, net760 3,058 
Total$23,609 $35,059 
Net of tax$18,373 $26,847 
Diluted EPS$0.56 $0.82 


(2) Adjusted EBITDA is defined as net (loss) income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3) Adjusted net service revenue is defined as net service revenue excluding certain items as described in footnote 1.
(4)    Adjusted net income attributable to Amedisys, Inc. is defined as net (loss) income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(5)    Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(6)    Adjusted EBITDA, adjusted net service revenue, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income
15

before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
16